ADR Biomedical Holdings (TSE:3750) Ending Cash Position: 円0.0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:3750 ADR Biomedical Holdings Inc TSE:3750
27 GF Score
Price 円826.00
GF Value 円38.94
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is ADR Biomedical Holdings Ending Cash Position?

ADR Biomedical Holdings TSE:3750 +0.49% 27 Ending Cash Position is 円0.0 Mil as of Mar. 2026. GuruFocus rates TSE:3750 with a GF Score™ of 27/100 and a GF Value™ of 円38.94 (Significantly Overvalued). The stock has 7 warning signs investors should review.

ADR Biomedical Holdings's Ending Cash Position for the quarter that ended in Mar. 2026 was 円0.0 Mil.

ADR Biomedical Holdings's annual Ending Cash Position declined from Mar. 2024 (円1,038.2 Mil) to Mar. 2025 (円256.0 Mil) and declined from Mar. 2025 (円256.0 Mil) to Mar. 2026 (円125.9 Mil).

ADR Biomedical Holdings Ending Cash Position Related Terms

ADR Biomedical Holdings Ending Cash Position Historical Data

* Premium members only.

The historical data trend for ADR Biomedical Holdings's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ADR Biomedical Holdings Ending Cash Position Chart

ADR Biomedical Holdings Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 701.56 673.05 1,038.23 255.98 125.90

ADR Biomedical Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TSE:3750
27GF Score
ADR Biomedical Holdings Inc TSE:3750
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ADR Biomedical Holdings Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

ADR Biomedical Holdings's Ending Cash Position for the fiscal year that ended in Mar. 2026 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=255.979+-130.078
=125.9

ADR Biomedical Holdings's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=0+0
=0.0

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of 円0.0 Mil mean?
ADR Biomedical Holdings (TSE:3750) has a Ending Cash Position of 円0.0 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on ADR Biomedical Holdings and its competitors.
Is ADR Biomedical Holdings' Ending Cash Position too high?
ADR Biomedical Holdings' current Ending Cash Position is 円0.0 Mil. Overall, ADR Biomedical Holdings has a GF Score™ of 27/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ADR Biomedical Holdings' Ending Cash Position compare to VRTX and REGN?
ADR Biomedical Holdings' Ending Cash Position of 円0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on ADR Biomedical Holdings and its competitors. ADR Biomedical Holdings's current Ending Cash Position is 円0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ADR Biomedical Holdings stock overvalued right now?
Based on GuruFocus' analysis, ADR Biomedical Holdings (TSE:3750) is currently considered Significantly Overvalued. The stock's GF Value™ is 円38.94, compared to a current price of 円826.00 — trading 2021.2% above its estimated fair value. The current Ending Cash Position is 円0.0 Mil. ADR Biomedical Holdings' overall GF Score™ is 27/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For ADR Biomedical Holdings (TSE:3750), the current Ending Cash Position is 円0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ADR Biomedical Holdings (TSE:3750) Overvalued in 2026?

Based on GuruFocus' analysis, ADR Biomedical Holdings stock appears to be overvalued. The current stock price of 円826.00 is trading 2021.2% above its estimated GF Value™ of 円38.94. GuruFocus considers ADR Biomedical Holdings to be Significantly Overvalued.

Key valuation signals for TSE:3750:

  • Ending Cash Position: 円0.0 Mil
  • GF Value™: 円38.94 vs. price of 円826.00 (2021.2% above fair value)
  • GF Score™: 27/100 with 7 warning signs

No single metric tells the full story. See the TSE:3750 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ADR Biomedical Holdings Business Description

Address 1-1-1 Otemachi, Otemachi Park Building, Chiyoda-ku, Tokyo, JPN, 100-0004
ADR120S Inc developing a new clinical approach to cell therapy to provide medical care to patients by providing medical care that responds to unmet medical needs based on its regenerative medicine. Its product pipeline includes Habeo; ECCO-50 and others.
27GF Score

Get the complete analysis for TSE:3750

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円826.00
Price
円38.94
GF Value